Krystal Biotech (KRYS) Q1 FY26 earnings call

Krystal Biotech delivered robust Q1 FY26 results, driven by strong global VYJUVEK sales and continued pipeline progress. The company emphasized its financial discipline and the strategic advantage of its FDA platform technology designations, which streamline development. While navigating US market dynamics like insurance changes and patient treatment cadences, Krystal is expanding internationally and advancing multiple registrational studies, positioning for significant catalysts over the next 12-24 months.